Cell Biology Immune Response Treatment 
Broad Institute
MAY 21, 2025
The work of June, Levine, Rivire, and Sadelain laid the foundation for a whole new class of treatments. The power of a patients immune system The idea of redirecting a persons own immune system to recognize and kill cancer cells had been around for decades, but how to do it effectively and safely remained a mystery.
Drug Target Review
OCTOBER 16, 2023
As we explore translatability, technological advancements and the integration of artificial intelligence (AI), we envision the potential role of PDOs throughout the entire medicine creation pipeline, from target identification to personalised clinical treatments, ultimately reducing costs and improving patient outcomes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
NOVEMBER 17, 2023
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
The Pharma Data
JANUARY 3, 2021
I look forward to working with Scott and his team at NexImmune to help advance and expand the Company’s research and development pipeline with the ultimate goal of developing next-generation immunotherapies for patients suffering from immune-mediated conditions related to cancers and autoimmune/inflammatory diseases,” Dr. Zeldis commented. “It
Broad Institute
OCTOBER 11, 2023
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. When I began my PhD I completely switched my focus, and I haven’t looked back,” said Manguso.
Drug Target Review
OCTOBER 2, 2024
Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. By correcting these mutations, gene-modifying and editing therapies hold the promise of long-term, potentially curative treatments.
The Pharma Data
DECEMBER 31, 2020
“Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford. Some of these patients mount a vigorous immune response, and others have a more moderate response. There are also other branches of the immune system involved.
Expert insights. Personalized for you.
119 
Let's personalize your content